Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

11. September 2025 12:00 ET | Quelle: Faraday Pharmaceuticals

Faraday Pharmaceuticals to Participate in Upcoming Investor Events

SEATTLE, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Faraday Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on preventing heart failure by reducing myocardial damage in acute...
24. April 2025 14:00 ET | Quelle: Faraday Pharmaceuticals

Faraday Pharmaceuticals to Host Satellite Symposium at SCAI 2025 on Exploring New Frontiers in Reducing Ischemia-Reperfusion Injury

SEATTLE, April 24, 2025 (GLOBE NEWSWIRE) -- Faraday Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on preventing heart failure by reducing myocardial damage in acute...
05. Februar 2025 10:00 ET | Quelle: Faraday Pharmaceuticals

Faraday Pharmaceuticals to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference

SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Faraday Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the prevention of heart failure by reducing myocardial damage in acute...
06. November 2024 13:21 ET | Quelle: Faraday Pharmaceuticals

Faraday Pharmaceuticals to Participate in Jefferies London Healthcare Conference

SEATTLE, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Faraday Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the prevention of heart failure by reducing myocardial damage...
16. Juli 2024 12:40 ET | Quelle: Faraday Pharmaceuticals

Faraday Pharmaceuticals to Host KOL Webinar on the Unmet Need in the Prevention of Ischemia-Reperfusion Injury in Acute STEMI

SEATTLE, July 16, 2024 (GLOBE NEWSWIRE) -- Faraday Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the prevention of heart failure by reducing myocardial damage...
11. Juni 2024 08:30 ET | Quelle: Faraday Pharmaceuticals

Faraday Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 Iocyte AMI-3 Trial of FDY-5301

2,300 patients in trial enrolled ahead of schedule12-month follow up period underway, with topline data anticipated in 2H 2025Trial designed with 90% power to detect a 30% reduction in the primary...
04. Januar 2024 15:05 ET | Quelle: Faraday Pharmaceuticals

Faraday Pharmaceuticals Announces Agreement with FDA on Interim Analysis of Phase 3 IOCYTE AMI-3 Trial Data and EU Notice of Intention to Grant Patent

Interim analysis estimated to occur in late Q2 2024 and will be based on at least 50% of anticipated primary outcomesPivotal Phase 3 trial continues to progress with over 75% of initially-planned...
10. Mai 2022 07:30 ET | Quelle: Faraday Pharmaceuticals

Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 3 Trial for Myocardial Infarction

SEATTLE, May 10, 2022 (GLOBE NEWSWIRE) -- Faraday Pharmaceuticals, Inc., today announced the enrollment of the first patient in its Iocyte AMI-3 study — a Phase 3 clinical trial assessing the...
27. Dezember 2021 08:30 ET | Quelle: Faraday Pharmaceuticals

Faraday Pharmaceuticals Announces Publication of Results from its Phase 2 Study of FDY-5301 for the Treatment of Reperfusion Injury Following a STEMI Heart Attack

SEATTLE, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Faraday Pharmaceuticals, Inc., a muscle health-focused biopharmaceutical company developing therapeutics to treat patients experiencing potentially life...
14. Oktober 2021 05:30 ET | Quelle: Faraday Pharmaceuticals

Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 2 Study for ICU-Acquired Weakness

SEATTLE, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Faraday Pharmaceuticals, Inc., a biopharmaceutical company dedicated to improving the quality of life for patients experiencing potentially life-changing...